Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Wnt/beta-catenin inhibitor
ICG-001 is a specific inhibitor of Wnt/β-catenin signaling pathway that inhibits β-catenin/cyclic AMP response element-binding (CREB) protein transcription (IC50=3 microM) .- Hong Gao, .et al. , Sci Rep, 2024, Oct 15;14(1):24182 PMID: 39406776
- Yun-Sheng Chen, .et al. , Research Square, 2024, August 16th
- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
- Seonmin Choi, .et al. , Yonsei Med J, 2021, Nov;62(11):1042-1051 PMID: 34672138
- Jasper C.Munro, .et al. , Livest Sci, 2019, 229 (2019) 159-169
- Kim JH, .et al. , Cell Rep, 2019, May 14;27(7):2105-2118.e5 PMID: 31091449
- Yamaoka R, .et al. , J Surg Oncol, 2018, Sep;118(4):664-674 PMID: 30196535
- Aida Y, .et al. , In Vitro Cell Dev Biol Anim, 2018, Jun;54(6):468-476 PMID: 29785536
-
Wnt inhibitor
IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription.- Charles A.Herring, .et al. , Cell, 2022, Oct 27;S0092-8674(22)01258-2 PMID: 36318921
-
β-Catenin/Tcf Inhibitor
FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.- Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
-
sFRP-1 inhibitor
WAY-316606 is a small molecule inhibitors of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. -
beta-catenin inhibitor
BC2059 is an orally bioavailable and potent beta-catenin inhibitor.- Ji-Hye Jung, .et al. , Stem Cells Dev, 2016, Jul 1; 25(13): 1006-1019 PMID: 27188501
-
Wnt/beta-catenin inhibitor
Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator with EC50 of 4.61 ?? 1.29 uM; also is an inhibitor of Wnt/beta-catenin signaling. -
Wnt/β-catenin signaling inhibitor
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. -
TET2 inhibitor
TFMB-(S)-2-HG is a potent inhibitor of TET2 and EglN prolyl hydroxylases. It downregulates Wnt3a and intranuclear β-catenin protein expression, and inhibits osteogenic differentiation of cells. TFMB-(S)-2-HG shows potential for research in acute myeloid leukemia (AML). -
Wnt/β-catenin Inhibitor
CCT036477 is a selective inhibitor of the Wnt/β-catenin signaling pathway that effectively disrupts β-catenin-mediated transcription without affecting its overall levels. This compound demonstrates significant anti-proliferative effects on various cancer cell lines and impairs embryonic development. Additionally, CCT036477 downregulates the expression of key Wnt target genes, including PPARδ, Cyclin D1, TCF4, and ID2, making it a valuable tool for research in cancer biology and developmental studies. -
Wnt/β-Catenin Inhibitor
MSAB is a potent and selective Wnt/β-catenin signaling inhibitor. By binding to β-catenin, it promotes its degradation and effectively downregulates Wnt/β-catenin target genes. MSAB demonstrates significant anti-tumor activity, particularly in Wnt-dependent cancer cell lines, making it a valuable tool for cancer research and therapeutic development targeting aberrant Wnt signaling. -
DKK1 Inhibitor
Gallocyanine chloride is a DKK1 inhibitor that targets the DKK1/LRP6 interaction, exhibiting an IC50 of 6.38 μM. This compound is relevant for research into Alzheimer's disease and related neurodegenerative tauopathies, as it activates the Wnt signaling pathway and promotes β-catenin accumulation. Additionally, Gallocyanine chloride demonstrates anti-metastatic, anti-inflammatory, and anti-fibrotic properties, and can serve as a fluorescent probe for the detection of superoxide anion radicals. -
Wnt/β-catenin/NF-κB/AP-1 Inhibitor
Chikusetsusaponin IVa methyl ester is a natural triterpenoid saponin that functions as a Wnt/β-catenin, NF-κB, and AP-1 inhibitor. It induces G0/G1 cell cycle arrest and apoptosis in colon cancer cells through the inhibition of the Wnt/β-catenin signaling pathway. Additionally, this compound significantly decreases the production of nitric oxide, prostaglandin E₂, and pro-inflammatory cytokines, while downregulating iNOS and COX-2 levels. Chikusetsusaponin IVa methyl ester is valuable for research focused on colorectal cancer and inflammatory processes. -
Wnt/β-catenin Inhibitor
Windorphen is a selective Wnt/β-catenin signaling inhibitor that specifically interferes with the c-terminal transactivation domain of β-catenin-1, while leaving β-catenin-2 unaffected. This compound targets p300, effectively disrupting the interaction between β-catenin and p300 without impacting CBP. Windorphen is valuable for research applications focused on β-catenin-related pathways, cancer biology, and developmental processes. -
Wnt/β-catenin Inhibitor
KWZY-11 is a potent Wnt/β-catenin inhibitor that effectively modulates the associated signaling pathway. This compound demonstrates strong biological activity by inducing DNA damage and promoting apoptosis specifically in MDA-MB-231 breast cancer cells. Its dual inhibition of PARP and CDK6 enhances its potential applications in cancer research, particularly for therapeutic strategies targeting tumor cell proliferation. -
β-catenin Inhibitor
β-catenin-IN-9 is a potent inhibitor of β-catenin, a key regulator in various signaling pathways. It has been shown to induce apoptosis and cell cycle arrest, while effectively inhibiting migration, invasion, and epithelial-mesenchymal transition (EMT) in colorectal cancer cells. Additionally, β-catenin-IN-9 suppresses the transcription of β-catenin and vimentin, leading to significant reductions in β-catenin protein levels. This reagent is valuable for research focused on colorectal cancer and related signaling pathways. -
β-catenin Inhibitor
Zolucatetide is a potent inhibitor of β-catenin, demonstrating an IC50 of less than 50 nM. It disrupts the interaction between β-catenin and the T-cell factor (TCF) transcription factor, leading to inhibited cell proliferation and induced cell cycle arrest in sensitive cell lines. In preclinical studies, Zolucatetide exhibits notable anti-tumor efficacy in xenograft models of colon cancer, specifically in COLO320DM cells with APC and TP53 mutations. This compound is valuable for research focused on colon cancer and related pathways. -
β catenin/BCL9 PPI Inhibitor
ZW4864 is a selective inhibitor of the β-catenin/B-Cell lymphoma 9 (BCL9) protein-protein interaction. It demonstrates potent inhibition with a Ki value of 0.76 μM and an IC50 of 0.87 μM. This compound is valuable for research applications targeting the Wnt signaling pathway in cancer biology, particularly in studies related to tumor progression and development. -
β-catenin Inhibitor
NRX-252262 is a potent β-catenin inhibitor that enhances the interaction between β-catenin and its E3 ligase, SCFβ-TrCP, facilitating the degradation of mutant β-catenin. With an EC50 of 3.8 nM, it serves as a valuable tool for studying the Wnt signaling pathway and its implications in various cancers and developmental processes. This compound is useful in research applications focused on β-catenin dysregulation and therapeutic strategies targeting Wnt-mediated pathways. -
β-Catenin Inhibitor
β-Catenin-IN-2 is a potent inhibitor of β-catenin, a key regulator in the Wnt signaling pathway. This compound demonstrates significant biological activity in various cancer models, particularly in the study of colorectal cancer. Research applications include investigating the role of β-catenin in tumorigenesis and exploring potential therapeutic interventions targeting this pathway. -
β-catenin Inhibitor
β-catenin-IN-3 is a selective inhibitor of β-catenin, targeting a cryptic allosteric modulation site with a binding affinity of K D 54.96 nM. This compound effectively reduces the viability of β-catenin-driven cancer cells by promoting degradation of β-catenin through the proteasome pathway. β-catenin-IN-3 is valuable for research applications focused on cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
Wnt/β-catenin inhibitor
2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research. -
β catenin/BCL9 PPI Inhibitor
ZW4864 free base is a selective inhibitor of the β-catenin/BCL9 protein-protein interaction. It exhibits significant inhibitory activity with a Ki value of 0.76 μM and an IC50 value of 0.87 μM, making it a valuable tool for researching β-catenin signaling pathways. This compound is particularly relevant for studies related to cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin/Tcf PPI Inhibitor
UU-T02 is a selective small-molecule inhibitor targeting the β-catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI), exhibiting a Ki value of 1.36 μM. This compound effectively inhibits canonical Wnt signaling pathways, demonstrating significant potential in suppressing the growth of colorectal cancer cells. Its application in research is valuable for understanding Wnt-related mechanisms in cancer biology and developing therapeutic strategies. -
β-catenin/BCL9 Inhibitor
Antitumor agent-172 is a selective β-catenin/BCL9 inhibitor, demonstrating an IC50 of 3.92 μM and a high binding affinity with a Kd of 82 nM. This compound activates T cells and enhances antigen presentation, thereby exhibiting significant antitumor efficacy. It also displays favorable pharmacokinetic properties in mouse models, making it a valuable tool for cancer research and therapy. -
wnt/β-catenin Inhibitor
Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases. -
β-catenin/BCL9 Inhibitor
Antitumor agent-171 is a potent inhibitor of the β-catenin/BCL9 interaction, demonstrating an IC50 value of 1.61 μM. This compound exhibits a strong binding affinity to β-catenin, with a Kd of 0.63 μM, and effectively inhibits the expression of the axin2 gene with an IC50 of 0.84 μM. Additionally, Antitumor agent-171 reduces cell viability in HCT116 cells at an IC50 of 4.39 μM. Its ability to activate T cells and enhance antigen presentation underscores its potential in antitumor applications, with favorable pharmacokinetic properties observed in mouse models. -
β-catenin/Tcf PPI Inhibitor
UU-T01 is a selective inhibitor of the β-catenin/T-cell factor 4 (Tcf) protein-protein interaction, exhibiting a Ki value of 3.14 µM. This compound directly binds to β-catenin, with a dissociation constant (KD) of 0.531 µM. UU-T01 is valuable in research focused on Wnt signaling pathways and their implications in cellular processes such as proliferation and differentiation, offering potential insights into cancer biology and related disorders. -
β-catenin/Tcf PPI Inhibitor
β-catenin-IN-37 is a selective inhibitor of the β-catenin/T-cell factor (Tcf) protein-protein interaction. This compound effectively disrupts canonical Wnt signaling, exhibiting inhibitory activity against colorectal cancer cell lines SW480 and HCT116, with IC50 values of 20 μM and 31 μM, respectively. β-catenin-IN-37 is valuable for studying Wnt signaling pathways and their implications in cancer research. -
Wnt/β-Catenin Inhibitor
YW1128 is a potent Wnt/β-Catenin inhibitor that induces the proteasomal degradation of β-catenin, leading to the inhibition of Wnt/β-Catenin signaling pathways in cells. This compound significantly reduces hepatic lipid accumulation and enhances glucose tolerance in mice subjected to a high-fat diet, demonstrating an absence of noticeable toxicity. Furthermore, YW1128 downregulates genes associated with glucose and fatty acid anabolism, making it a valuable tool for research into metabolic disorders and Wnt signaling pathway modulation. -
β-catenin/TCF Signaling Inhibitor
CCT031374 hydrobromide is a potent inhibitor of the β-catenin/TCF signaling pathway. It effectively disrupts TCF-dependent transcription of target genes associated with the Wnt signaling cascade. CCT031374 demonstrates significant antitumor activity, making it valuable for research in cancer biology and therapeutic development targeting aberrant Wnt signaling. -
β-catenin Inhibitor
CGK012 is a selective β-catenin inhibitor that disrupts the Wnt/β-catenin signaling pathway. It effectively inhibits the release of HMGB1 and the transcriptional activity of β-catenin, demonstrating potential therapeutic benefits in sepsis induced by cecal ligation and puncture as well as in multiple myeloma. This compound is valuable for research applications focused on Wnt signaling regulation and its implications in various diseases. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-1 is a selective inhibitor targeting the PTK7/β-catenin signaling pathway, demonstrating an IC50 of 8.9 μM for PTK7/β-catenin and 56.5 μM for p53/MDM2. This compound shows promise in cancer research, particularly in studies examining the modulation of tumorigenic pathways influenced by β-catenin. Its inhibitory effects provide a valuable tool for investigating the role of PTK7 in cancer progression and therapeutic strategies. -
PTK7/β-catenin Inhibitor
PTK7/β-catenin-IN-6 is a selective inhibitor of the PTK7/β-catenin interaction, effectively disrupting the Wnt signaling pathway. This compound demonstrates significant anticancer activity, particularly in colorectal cancer (CRC) models, making it a valuable tool for cancer research and therapeutic studies targeting Wnt-related pathways. -
β-catenin Inhibitor
β-catenin-IN-4 is a potent inhibitor of β-catenin, exhibiting an inhibition constant (Ki) of 0.64 μM. This compound effectively decreases the protein expression levels of key oncogenic factors such as cyclin D1 and c-Myc. β-catenin-IN-4 is valuable for research applications focused on cancer biology, particularly in studies investigating the Wnt signaling pathway and its role in tumor progression. -
Wnt/β-catenin Signaling Pathway Inhibitor
Wnt/β-catenin-IN-2 is an inhibitor of the Wnt/β-catenin signaling pathway, displaying an IC50 value of 7.1 μM and a KD value of 2.5 μM. This compound is useful in cancer research, enabling the study of Wnt/β-catenin pathway modulation and its implications in tumorigenesis. Its application can enhance understanding of the mechanistic roles of this pathway in various malignancies. -
β-catenin Inhibitor
β-catenin-IN-6 is an inhibitor of β-catenin, effectively disrupting the canonical Wingless-related integration site signaling pathway. This compound demonstrates significant anti-proliferative effects on human colorectal cancer cells and has been shown to inhibit tumor growth in a β-catenin/RK3E mouse model, making it a valuable reagent for cancer research and therapeutic studies targeting β-catenin signaling pathways. -
β-catenin/BCL9 Complex Inhibitor
E722-2648 is a selective inhibitor of the β-catenin/BCL9 complex, targeting the interaction between these two proteins to inhibit β-catenin-mediated transcriptional activity. This compound demonstrates significant antitumor activity by downregulating the expression of WNT target genes, effectively suppressing tumor growth in colon cancer xenograft and colorectal cancer mouse models. E722-2648 serves as a valuable tool for investigating the molecular mechanisms of colon and colorectal cancers. -
Wnt/β-catenin Signal Inhibitor
KP-6 is a polypeptide that acts as a Wnt/β-catenin signaling pathway inhibitor. By inhibiting TGF-β, KP-6 disrupts critical fibrotic signaling pathways in vivo, effectively reducing renal tissue damage and fibrotic progression. This compound holds promise for research focused on chronic kidney disease (CKD) and other fibrosis-related disorders, making it a valuable tool for studying disease mechanisms and potential therapeutic interventions. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-5 is a potent inhibitor of the Wnt/β-catenin signaling pathway. This compound demonstrates significant inhibition of cell proliferation in HCT 116, SW480, and A549 cell lines, with IC50 values of 3.05 μM, 3.27 μM, and 34.91 μM, respectively. It serves as a valuable tool for research focused on cancer biology and the role of Wnt signaling in tumor development and progression. -
β-catenin:TCF Interaction Inhibitor
β-Catenin inhibitory peptoid targets the β-catenin:TCF interaction, exhibiting an IC50 of 5.44 µM. This compound effectively inhibits Wnt signaling with an IC50 of 0.105 µM and androgen receptor signaling with an IC50 of 1.02 µM in prostate cancer cell lines. The peptoid significantly reduces cell proliferation, making it a valuable tool for research in cancer biology and therapeutic development. -
Wnt/β-catenin Inhibitor
Wnt/β-catenin-IN-3 is a potent inhibitor of the Wnt/β-catenin signaling pathway, demonstrating low micromolar GI50 values across various cancer cell lines. This compound induces G2/M cell cycle arrest by activating the p53-p21 pathway and promotes apoptotic cell death through both intrinsic and extrinsic mechanisms in colon cancer cells. It serves as a valuable tool for investigating the role of Wnt/β-catenin signaling in cancer biology and therapeutic applications. -
Wnt/β-catenin Inhibitor
Getacatetide is a peptide-based inhibitor of the Wnt/β-catenin signaling pathway. This compound is designed to interfere with the activation of Wnt target genes, making it a valuable tool for investigating the role of Wnt/β-catenin signaling in solid tumors. Getacatetide's ability to disrupt this pathway facilitates research into cancer biology and the development of potential therapeutic strategies. -
Axin Phosphorylation Inhibitor; β-catenin Phosphorylation Inhibitor
FRATtide is a peptide inhibitor targeting GSK-3, effectively disrupting the phosphorylation of Axin and β-catenin. By preventing the binding of GSK-3 to Axin, FRATtide modulates the Wnt signaling pathway, making it a valuable tool for research in cancer biology and developmental processes. This reagent is essential for studying mechanisms of β-catenin regulation and its implications in various diseases.
